PTC Therapeutics (BH3) Financial Statements
PTC Therapeutics Financial Overview
PTC Therapeutics's market cap is currently $4.47B. The company's EPS TTM is $-1.31; its P/E ratio is -45.78; PTC Therapeutics is scheduled to report earnings on February 23, 2027, and the estimated EPS forecast is $0.24. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.73B | $ 806.78M | $ 937.82M | $ 698.80M | $ 538.59M |
| Gross Profit | $ 1.66B | $ 749.38M | $ 872.34M | $ 654.12M | $ 506.26M |
| Operating Income | $ 856.51M | $ -302.57M | $ -439.50M | $ -447.41M | $ -374.44M |
| EBITDA | $ 887.66M | $ -120.46M | $ -330.34M | $ -367.78M | $ -368.18M |
| Net Income | $ 682.64M | $ -363.30M | $ -626.60M | $ -559.02M | $ -523.90M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.95B | $ 1.14B | $ 876.74M | $ 410.70M | $ 773.38M |
| Total Assets | $ 2.90B | $ 1.71B | $ 1.90B | $ 1.71B | $ 1.94B |
| Total Debt | $ 2.71B | $ 2.47B | $ 2.23B | $ 1.46B | $ 1.27B |
| Net Debt | $ 1.72B | $ 1.69B | $ 1.64B | $ 1.18B | $ 1.08B |
| Total Liabilities | $ 3.10B | $ 2.80B | $ 2.71B | $ 2.05B | $ 1.94B |
| Stockholders' Equity | $ -205.31M | $ -1.10B | $ -818.55M | $ -347.09M | $ 1.44M |
| Cash Flow | |||||
| Free Cash Flow | $ 411.18M | $ -181.94M | $ -279.04M | $ -509.11M | $ -336.66M |
| Operating Cash Flow | $ 711.20M | $ -107.69M | $ -158.42M | $ -356.65M | $ -251.33M |
| Investing Cash Flow | $ -861.98M | $ 44.18M | $ -176.74M | $ 290.18M | $ 219.18M |
| Financing Cash Flow | $ 331.09M | $ 255.87M | $ 646.40M | $ 167.95M | $ 20.88M |
Currency in USD